About Tourmaline Bio
Tourmaline Bio is a publicly listed company based in New York (United States) founded in 2021, and was acquired by Novartis in September 2025. Therapeutics for immune disorders are developed by Tourmaline Bio. It operates on a HealthTech model. Tourmaline Bio offers products and services including Transformative Medicines. Its focus areas include Biotechnology and Inflammatory and Immune Diseases. Its legal entity is Tourmaline Bio, Inc. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Tourmaline Bio is focused on the development of transformative medicines aimed at establishing new standards of care for patients with life-altering inflammatory and immune diseases. The company operates in the healthcare sector, specifically targeting areas with high unmet medical needs. Solutions are crafted by a dedicated team of entrepreneurs, physicians, and industry experts committed to advancing patient care through innovative pharmaceutical approaches.
- Headquarters New York, United States
- Stage Public
- SectorsHealthcare
- Website tourmalinebio.com
- Social LinkedIn
- Acquired by Novartis (Sep 2025)
- Legal Name Tourmaline Bio, Inc.
Products & Services of Tourmaline Bio
Tourmaline Bio offers a comprehensive portfolio of products and services, including Transformative Medicines.
Medicines are developed for inflammatory and immune diseases.
Investors in Tourmaline Bio
Tourmaline Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Tourmaline Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Tourmaline Bio
36 people are tracked at Tourmaline Bio (25 in leadership, 11 in team).
| Name | Role | Group |
|---|---|---|
Christopher Brown | Senior Director Of Technical Operations | Leadership |
Ryan Robinson | Chief Financial Officer & Treasurer | Leadership |
Sandeep Kulkarni | Chief Executive Officer | Leadership |
Carole Koveleski | Director, Quality Compliance | Leadership |
Alex Meyer | Senior Director Of People, Culture And Compliance | Leadership |
Susan D. Jones | Chief Technology Officer | Leadership |
Brad Middlekauff | Chief Business Officer And General Counsel | Leadership |
Susan Dana Jones | Chief Technology Officer | Leadership |
Gerhard Hagn | Chief Commercial Officer (cco) Heading Commercial And Business Development | Leadership |
Clarissa Wheeler | Associate Director, Clinical Trial Liaison | Leadership |
Chris Beans | Head Of IT | Leadership |
Tory Trippe | Senior Director, Finance And Corporate Development | Leadership |
Ryan Iarrobino | Senior Vice President, Product Development | Leadership |
Monica Louie | Director, Cmc, Quality Assurance | Leadership |
Famina Hemani | Vice President, Head Of Pharmacovigilance | Leadership |
Dora Rau | Senior Vice President, Head Of Quality | Leadership |
Frances Bai | Director Program Management | Leadership |
Jennessa M. | Director | Leadership |
Aminah Sayid | Associate Director, People & Culture | Leadership |
Eric Nord | Associate Director Of Analytical Development | Leadership |
16 more people are available in the full profile.
Complete people profiles for Tourmaline Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Tourmaline Bio
Tourmaline Bio is a publicly listed company on the NASDAQ with ticker symbol TRML in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- Listed onNASDAQ: TRML
- Listed entityTourmaline Bio, Inc.
- Exchange sectorHealth technology
- Share price$47.74 (+0.04% on the day) · 2025-09-29
- Market capitalisation$1.23B
- EPS (diluted, trailing year)$-3.44
- Volume (last session)963,516
- Analyst consensusNeutral
Financials of Tourmaline Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$73.2M | -$89.7M | |
| 2023 | -$42.1M | -$45.4M | |
| 2022 | -$19.7M | -$19.7M | |
| 2021 | -$47.8M | -$46.9M |
Detailed financial statements for Tourmaline Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Tourmaline Bio
2 dated milestones of Tourmaline Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Tourmaline Bio is founded.
- Exit Acquired by Novartis.
Competitors of Tourmaline Bio
Tourmaline Bio has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Tourmaline Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Tourmaline Bio
The website of Tourmaline Bio (tourmalinebio.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▼ 7.6% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Tourmaline Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tourmaline Bio
Complete news archive for Tourmaline Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tourmaline Bio
Tourmaline Bio was founded in 2021.
Tourmaline Bio is headquartered in New York, United States. It is registered at New York, New York, United States.
Tourmaline Bio is focused on the development of transformative medicines aimed at establishing new standards of care for patients with life-altering inflammatory and immune diseases. The company operates in the healthcare sector, specifically targeting areas with high unmet medical needs. Solutions are crafted by a dedicated team of entrepreneurs, physicians, and industry experts committed to advancing patient care through innovative pharmaceutical approaches.
Tourmaline Bio's top competitors include ADMA Biologics, Kymeratx and Biogen.
Tourmaline Bio offers Transformative Medicines.
Yes, Tourmaline Bio is publicly traded on NASDAQ under the ticker symbol TRML.
Tourmaline Bio has 1 investor. Key investors include Novartis.
Tourmaline Bio operates through Tourmaline Bio, Inc..
Yes. Tourmaline Bio was acquired by Novartis in September 2025.

